Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Schizophrenia
Interventions: inhaled Loxapine 0.625 mg, inhaled Loxapine 1.25 mg, inhaled Loxapine 2.5 mg, inhaled Loxapine 5 mg, inhaled Loxapine 10 mg, inhaled Placebo (0 mg); Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Alcohol Use Disorder
Interventions: NTX-2001, Placebo; Drug
Lead sponsor: Newleos Therapeutics, Inc.; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obstructive Sleep Apnea
Interventions: Active CPAP, Sham CPAP; Device
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 30 Years to 70 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Torrance, California

Conditions: Schizophrenia
Interventions: ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Glendale, California • New York, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: LGD-6972, Placebo (Captisol ®); Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Tempe, Arizona • Miami, Florida • Cincinnati, Ohio

Conditions: Ocular Myasthenia Gravis
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Michael Benatar; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: New Haven, Connecticut • Miami, Florida • Kansas City, Kansas + 5 more

Conditions: Depression
Interventions: Creatine monohydrate, Placebo; Drug
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Asthma
Interventions: QAV680, QAV680 Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Cypress, California • Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Hyperalgesia
Interventions: Remifentanil, Remifentanil+ Placebo, Remifentanil +ultra-low dose naloxone; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Orange, California

Conditions: Healthy
Interventions: MEDI-534, Cohort 1, Placebo, Cohort 1, MEDI-534, Cohort 2, Placebo, Cohort 2, MEDI-534, Cohort 3, Placebo, Cohort 3, MEDI-534, Cohort 4, Placebo, Cohort 4, MEDI-534, Cohort 5, Placebo, Cohort 5; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 2 Months to 23 Months
Enrollment: 1,338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 51
States / cities: Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more

Conditions: Pain, Virtual Reality, Placebo, Temporomandibular Disorder
Interventions: Active Virtual Reality, sham Virtual Reality, No Intervention, Naloxone, Saline, Natural history; Behavioral · Other · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: sodium nitroprusside, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Glen Oaks, New York + 1 more

Conditions: Endometriosis
Interventions: Vitamin D3, Fish Oil, Placebo; Dietary Supplement · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 25 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Hypertriglyceridemia
Interventions: Pegozafermin, Placebo; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 73
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 65 more

Conditions: Cirrhosis, Liver
Interventions: Epigallocatechin gallate (EGCG), Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ocular Surface Disease
Interventions: Fishoil supplement, Olive Oil; Dietary Supplement
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoporosis, Frailty
Interventions: DHEA, Yoga, Placebo, Aerobics; Dietary Supplement · Behavioral
Lead sponsor: National Aeronautics and Space Administration (NASA); Federal
Eligibility: 65 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Psychological Stress, Hypertension, Renal
Interventions: mycophenolate mofetil (MMF), Placebo; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Cannabis Use Disorder
Interventions: N-acetyl cysteine, Placebo oral capsule; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 14 Years to 21 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Diaphragm Injury
Interventions: Tofacitinib 10 MG [Xeljanz], Placebo to match Tofacitinib; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Depression, Menopause, Vasomotor Symptoms
Interventions: Duloxetine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19 Pneumonia, Vascular Complications
Interventions: Placebo, Dipyridamole Tablets; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Healthy
Interventions: Monovalent influenza virus vaccine, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 3
States / cities: Daytona Beach, Florida • Portland, Oregon • Austin, Texas

Conditions: Wellness, Health
Interventions: Ubiquinol + geranylgeraniol, Geranylgeraniol, Ubiquinol, Ubiquinone, Placebo; Dietary Supplement · Other
Lead sponsor: OvationLab; Network
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: El Dorado Hills, California • Centennial, Colorado • Palm Springs, Florida + 3 more

Search by objective public record fields.

Staccato Loxapine Single Dose PK

Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder

Reproductive Aging and Obstructive Sleep Apnea

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus

Efficacy of Prednisone In the Treatment of Ocular Myasthenia

Creatine Monohydrate Use for Preventing Altitude Induced Depression

Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia

Supplementation in Adolescent Girls With Endometriosis

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

EGCG for Hepatocellular Carcinoma Chemoprevention

Omega 3 Supplementation and Ocular Surface Disease in Glaucoma

Effects of DHEA/Exercise on Bone, Muscle and Balance

Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress

N-Acetylcysteine for Youth Cannabis Use Disorder

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Duloxetine for Menopausal Depression

Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations